Connect Biopharma Holdings Ltd (CNTB) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Connect Biopharma Holdings Ltd (CNTB) has a cash flow conversion efficiency ratio of -0.314x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-17.41 Million) by net assets ($55.37 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Connect Biopharma Holdings Ltd - Cash Flow Conversion Efficiency Trend (2018–2024)
This chart illustrates how Connect Biopharma Holdings Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read CNTB total liabilities for a breakdown of total debt and financial obligations.
Connect Biopharma Holdings Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Connect Biopharma Holdings Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Asian Hotels (North) Limited
NSE:ASIANHOTNR
|
-0.675x |
|
Bapcor Ltd
AU:BAP
|
0.032x |
|
Genesis Technology
TWO:6221
|
-0.072x |
|
Shree Pushkar Chemicals & Fertilisers Limited
NSE:SHREEPUSHK
|
0.065x |
|
Acres Commercial Realty Corp
NYSE:ACR
|
-0.022x |
|
Baozun Inc
NASDAQ:BZUN
|
0.000x |
|
AMPACS Corp.
TW:6743
|
-0.113x |
|
Wam Alternative Assets Ltd
AU:WMA
|
-0.026x |
Annual Cash Flow Conversion Efficiency for Connect Biopharma Holdings Ltd (2018–2024)
The table below shows the annual cash flow conversion efficiency of Connect Biopharma Holdings Ltd from 2018 to 2024. For the full company profile with market capitalisation and key ratios, see Connect Biopharma Holdings Ltd market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $92.17 Million | $-23.61 Million | -0.256x | +45.99% |
| 2023-12-31 | $101.04 Million | $-47.93 Million | -0.474x | +23.45% |
| 2022-12-31 | $160.21 Million | $-99.27 Million | -0.620x | +69.01% |
| 2021-12-31 | $272.57 Million | $-544.93 Million | -1.999x | -1325.81% |
| 2020-12-31 | $-157.01 Million | $-25.61 Million | 0.163x | -46.10% |
| 2019-12-31 | $-43.27 Million | $-13.09 Million | 0.303x | -91.49% |
| 2018-12-31 | $-19.41 Million | $-69.03 Million | 3.556x | -- |
About Connect Biopharma Holdings Ltd
Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of inflammatory diseases in the United States. The company's lead product candidate is rademikibart (formerly CBP-201), an antibody designed to target interleukin-4 receptor alpha, which is in Phase 3 studies for the treatment of inflammatory diseases such as a… Read more